In this issue:
Hepatic perfusion with melphalan in uveal melanoma
Retreatment of cutaneous melanoma relapse after ICI therapy
Surgical outcomes for lymph node dissection
Nivolumab and relatlimab use for advanced melanoma
Influence of melanoma type on the incidence and downstream implications of cirAEs
Adjuvant therapy for stage III BRAF-mut melanoma
Treatment-free survival after nivolumab vs pembrolizumab vs nivolumab-ipilimumab
Blood myeloid-derived suppressor cells and ICI for advanced melanoma
ICI in patients with NRAS mutated and NRAS wild-type melanoma
Please login below to download this issue (PDF)